BACKGROUND: Concurrent chemoradiation therapy (CRT) is the current standard of care for @entity1 with locally advanced @entity2220 ; however, little has been reported about the impact of @entity470 mutation on CRT efficacy. METHODS: From 2006-2013, we retrospectively screened 104 unresectable stage III @entity420 @entity1 who were examined for @entity470 mutation status and received definitive concurrent CRT consisting of @entity902 doublet chemotherapy in first-line setting, and compared the clinical outcomes and recurrence patterns according to mutation status. RESULTS: Among 104 @entity1 , @entity470 mutation was detected in 29 (28%). The overall response rate did not differ between @entity470 -mutant and wild-type @entity1 (72.4% vs. 72.0%, p=0.607). The median progression-free survival (PFS) in concurrent CRT was significantly shorter in @entity470 -mutant @entity1 than in wild-type @entity1 (9.8 [95%CI: 7.6-19.0] vs. 16.5 [95%CI: 11.8-19.9] months, p=0.041). The 2-year recurrence-free survival rate was 7.7% and 28.1% in @entity470 -mutant and wild-type @entity1 , respectively (p=0.028). Distant metastases were more frequently identified as the first recurrence site in @entity470 -mutant @entity1 than in wild-type @entity1 (76% vs. 40%, p=0.001). The brain was the most commonly affected site in @entity470 -mutant @entity1 (35%). However, locoregional recurrence was less common in @entity470 -mutant @entity1 than in the wild-type population (14% vs. 35%, p=0.027). @entity1349 ( @entity1349 ) was similar between @entity470 -mutant and wild-type @entity1 (51.1 [95%CI: 28.2-70.2] vs. 42.9 [95%CI: 35.3-NA] months, p=0.637). Among the @entity470 wild-type population who were examined for @entity984 mutation, @entity984 -mutant @entity1 had significantly worse @entity1349 than @entity984 wild-type @entity1 (21.6 vs. 49.8 months, p=0.024). CONCLUSION: Concurrent CRT resulted in shorter PFS in @entity470 -mutant stage III @entity420 @entity1 than in wild-type @entity1 , mainly due to distant metastasis relapse, regardless of better local control. Because of these distinct biological features, a different strategy, including @entity470 -TKIs for @entity470 -mutant, locally advanced @entity420 @entity1 receiving definitive CRT may be needed.

XXXX MutationImpact on DefinitiveConcurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity984 :: ('3845', 'Gene') :: ['Kras'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival']
@entity470 :: (1956,Gene) :: ['EGFR']
